Abstract
Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.
| Original language | English |
|---|---|
| Pages (from-to) | 559-570 |
| Number of pages | 12 |
| Journal | Drug Safety |
| Volume | 40 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Jul 1 2017 |
Fingerprint
ASJC Scopus subject areas
- Toxicology
- Pharmacology
- Pharmacology (medical)
Cite this
Targeting Interleukin-5 or Interleukin-5Rα : Safety Considerations. / Bagnasco, Diego; Ferrando, Matteo; Caminati, Marco; Bragantini, Alice; Puggioni, Francesca; Varricchi, Gilda; Passalacqua, Giovanni; Canonica, Giorgio Walter.
In: Drug Safety, Vol. 40, No. 7, 01.07.2017, p. 559-570.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Targeting Interleukin-5 or Interleukin-5Rα
T2 - Safety Considerations
AU - Bagnasco, Diego
AU - Ferrando, Matteo
AU - Caminati, Marco
AU - Bragantini, Alice
AU - Puggioni, Francesca
AU - Varricchi, Gilda
AU - Passalacqua, Giovanni
AU - Canonica, Giorgio Walter
PY - 2017/7/1
Y1 - 2017/7/1
N2 - Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.
AB - Asthma is a highly prevalent chronic disease of the airways; approximately 10% of patients with asthma will experience a severe form of the disease. New understanding of the pathogenesis of asthma has enabled the development of novel drugs and provided hope for patients with asthma. Interleukin (IL)-5 and IL-5 receptor subunit α (IL-5-Rα) plays a crucial role in the development, maturation, and operation of eosinophils so were the first important therapeutic target of these new drugs. While the results of early clinical trials of these drugs were not promising, results improved once researchers discovered the drugs worked best in patients with high eosinophil levels. Patients treated with both anti-IL-5 and IL-5-Rα experienced significant decreases in exacerbations. Trials have also demonstrated promising safety profiles; adverse events have been few and frequently only observed with placebo or considered unrelated to the study drug. The positive efficacy and safety profiles of these drugs has led to trials with interesting results in other diseases that are also secondary to the action of eosinophils: Churg–Strauss syndrome, hypereosinophilic syndrome, nasal polyposis, chronic obstructive pulmonary disease, atopic dermatitis, and esophagitis. In this review, we explore the main clinical trials of anti-IL-5 and IL-5-Rα, both in asthma and in other pathologies, with particular reference to the interesting safety and efficacy results.
UR - http://www.scopus.com/inward/record.url?scp=85021338013&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85021338013&partnerID=8YFLogxK
U2 - 10.1007/s40264-017-0522-5
DO - 10.1007/s40264-017-0522-5
M3 - Review article
AN - SCOPUS:85021338013
VL - 40
SP - 559
EP - 570
JO - Drug Safety
JF - Drug Safety
SN - 0114-5916
IS - 7
ER -